AzTrials
AzTrials

Cerebral PalsyEMBRINNCT06533956

Gait Training Program With Blood Flow Restriction in Children With Cerebral Palsy - EMBRIN: Pilot Study

A study testing 10-week gait training program combined with simultaneous blood flow restriction (BFR). in people with Cerebral Palsy, run by University Hospital, Angers at 2 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a single-center prospective experimental pilot study to assess the feasibility, tolerability and effect of a 10-week gait training program combined with simultaneous blood flow restriction (BFR) on the walking speed of children, aged 8 to 18, with bilateral spastic cerebral palsy. Read more about this study

Who is it for?
Ages 8 to 18 years
Conditions the study is for
Cerebral Palsy
What is being tested?
10-week gait training program combined with simultaneous blood flow restriction (BFR).
Could I receive a placebo?
No, everyone receives an active treatment
How many people
13 participants
Where
2 sitesFrance
Study dates
31 Oct 2024to 1 Oct 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Patients aged 8 to 18 with bilateral spastic cerebral palsy
  • Patient with functional level II or III according to the Gross Motor Function Classification System (GMFCS)
  • Patient able to assess pain with NRS-11
  • Patient able to walk on a treadmill without body weight support, with or without technical aids
  • Patient able to perform the 10-meter walk test
  • No skin pathology at the pressure cuff application site (eczema, inflammatory scarring, etc.)
  • Patient affiliated to or benefiting from a social security scheme
  • Informed consent, dated and signed by parents or guardians (if a minor) or by the patient (if of age), to participate in the study;

Who cannot join

  • Patients who have undergone surgical treatment or intramuscular injections of botulinum toxin in the lower limbs within the last 3 months
  • Patients with a history of arterial hypertension, thrombo-embolic events, thrombophilia or cancer.
  • Patient with insufficient understanding of the French language;
  • Opposition of the patient (child or adolescent);
  • Pregnant, breast-feeding or parturient women;
  • Persons deprived of their liberty by judicial or administrative decision;
  • Persons under compulsory psychiatric care;
  • Persons under legal protection

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

France2 sites, 2 recruiting
  • Les Capucins

    Angers

    Adélie Christiaens

    Recruiting
  • University Hospital, Angers

    Angers

    Adélie Christiaens, 2 41 35 36 37 ext. +33, adelie.christiaens@univ-angers.fr

    Not yet recruiting

Other trials in France

About this study

Official title: Programme d'Entrainement à la Marche Avec Blood Flow RestrIctioN Chez l'Enfant Avec Paralysie cérébrale - EMBRIN: Etude Pilote

This is a single-center prospective experimental pilot study to assess the feasibility, tolerability and effect of a 10-week gait training program combined with simultaneous blood flow restriction (BFR) on the walking speed of children, aged 8 to 18, with bilateral spastic cerebral palsy.

The children will receive a 10-week intervention (1 week of habituation without BFR + 9 weeks with BFR) comprising 3 30-minute treadmill sessions per week. At each session, the first 5 minutes will enable a gradual increase in speed, and then the maximum tolerated walking speed will be sought. Maximum speed corresponds to the walking speed maintained by the child for an effort of between 5 and 7 on Borg's 10-point VAS. The rehabilitator will encourage the child to maintain this speed and provide feedback on performance. The BFR setting will maintain an occlusion, at the root level of both lower limbs, of 60% of the total occlusal pressure.

Children receiving the 10-week EMBRIN program are expected to improve their walking ability and muscular strength, two targets recognized as priorities for individuals with CP by the HAS. In this population, a major limitation of implementing rehabilitation programs is the large amount of practice required to bring about significant changes. This large amount of practice requires a major investment on the part of the individual, as well as significant rehabilitation resources. Muscle-strengthening programs are also particularly repetitive and therefore not very motivating for children. The EMBRIN program could reduce the training load and duration required to impact functional performance in children with CP. It could also help reduce the cost of rehabilitation interventions and reduce physical therapy time for individuals with CP in favor of their social participation.

Read the detailed description

Context :

Cerebral palsy (CP) is the leading cause of motor disability in children, with a prevalence of 1.77 cases per 1000 births. It is defined as a set of permanent developmental disorders of movement and posture, resulting from a non-progressive brain lesion affecting a developing brain. 60% of individuals with CP have a bilateral form. In this group, 98% of diplegics and 24% of quadriplegics will be "walkers", but more often than not with poor walking efficiency. In fact, these children show not only a reduction in walking speed, but also markedly reduced endurance. What's more, these children have reduced levels of physical activity, resulting in less participation in physical activities throughout their lives. Associated with these changes in motor activity, CP leads to morphological and architectural changes in the muscles, including reduced muscle volume, shorter muscle fascicles and increased intramuscular fat. These "bad" adaptations contribute to a reduction in muscle strength and power, leading to a progressive decline in functional capacity in adolescence and adulthood, associated with a sedentary lifestyle. In individuals with CP, gait training and muscle strengthening programs, carried out separately, have shown, respectively, a relative efficacy in improving walking activity and lower limb muscle strength. Rare programs combining these two interventions have been shown to be of interest in mildly affected children. In the geriatric population (without CP), where strengthening with heavy loads may be contraindicated and difficult to implement, Blood Flow Restriction (BFR) training has attracted considerable interest due to its simplicity of use and effectiveness. Indeed, the application of an inflatable cuff to the proximal part of a limb restricting blood flow, combined with low-load muscle strengthening, has shown similar effects to high-load strengthening on muscle function. BFR was also combined with functional training, and this combination showed superiority over functional training alone in improving functional activity. BFR does not appear to cause side-effects in typical adolescents, and has never been studied in children with CP.

Objectives and evaluation criteria :

Primary objective: to study the effect of a 10-week gait training program combined with simultaneous blood flow restriction (BFR), using a commercially available device, on the walking speed of children aged 8 to 18 with bilateral spastic cerebral palsy. To this end, a comparison of patients' walking speed will be carried out between the period D-70 to D0 (standard rehabilitation) and the period D0 to D+70 (walking training program + BFR). Walking speed will be assessed by the 10-meter walk test. The evaluation criterion is the change in walking speed between D-70-J0 and D0-J+70.

Secondary objectives and evaluation criteria

To assess the effect of this gait training program combined with BFR on the following levels of the International Classification of Functioning and Disability:

Functions :

  • Isometric strength of plantar flexors, knee extended and flexed, by electronic hand dynamometer (DEM)
  • Isometric strength of knee flexors and extensors by DEM
  • Isometric strength of hip abductors by DEM
  • Pain intensity by numerical rating scale (NRS-11) (somato sensory function)

Activities :

  • Walking endurance by 6-minute walk test
  • Spontaneous and maximum walking speeds using the 10-meter walk test
  • Global motor activity via Gross Motor Function Measure - 66 (GMFM-66)
  • Spatial gait parameters: stride length, step length, base of support, step angle, and temporal gait parameters: speed and normalized speed, cadence, percentage of right and left support phase, right and left cycle time and double support time (Gaitrite)

Participation:

  • Achievement of functional goals in terms of performance and satisfaction using the Canadian Occupational Performance Measure (COPM)
  • Achievement of daily activities and mobility using the Pediatric Evaluation of Disability Inventory as a computer adaptive test (PEDI-CAT)
  • Evaluate the feasibility of this gait training program associated with BFR. Feasibility will be assessed by analyzing the percentage of children completing 80% of the training program.
  • To evaluate the tolerance of the EMBRIN program of this gait training program associated with BFR. Tolerance to the training program will be studied by assessing pain before, during and after gait training with the NRS-11 scale (23), as well as by notifying the occurrence of intercurrent medical events or complications. The evaluation criteria are :
  • Change in NRS-11 pain score during gait training sessions;
  • The occurrence of intercurrent medical events or complications.
  • Evaluate participant satisfaction using the CSQ-8 satisfaction questionnaire.

Research scheme and progress This is a single-center prospective experimental pilot study designed to assess the feasibility, tolerability and effect of a 10-week gait training program combined with simultaneous blood flow restriction (BFR) on the walking speed of children, aged 8 to 18, with bilateral spastic cerebral palsy. The children will receive a 10-week intervention (1 week of habituation without BFR + 9 weeks with BFR) comprising 3 30-minute treadmill sessions per week. At each session, the first 5 minutes will enable a gradual increase in speed, and then the maximum tolerated walking speed will be sought. Maximum speed corresponds to the walking speed maintained by the child for an effort of between 5 and 7 on Borg's 10-point VAS. The rehabilitator will encourage the child to maintain this speed and provide feedback on performance. The BFR setting will maintain an occlusion, at the root level of both lower limbs, of 60% of the total occlusal pressure.

During each session, pain will be assessed using the NRS-11 before the restriction is placed, after 15 minutes of walking and within 5 minutes of the restriction being removed. In the event of participant request or premature termination of the session, a pain assessment will be added. A pain assessment will also be carried out 24 hours after the training session.

Functional assessments carried out at baseline at T0 (D0-70d) and T1 (D0) will explore the usual evolution of walking speed in children receiving usual care. Assessments at T2 (D0+35d) will explore the evolution of variables of interest halfway through the intervention period. Evaluations at T3 (D0+70d) will assess the immediate effects of therapy. Functional assessments will be carried out again at T4 (D0+100d) and T5 (D0+160) to evaluate the medium-term effect of therapy.

Research duration Inclusion period: 24 months Duration of participation: 8 months maximum Study duration: 32 months

Conditions
Cerebral Palsy
Being tested
10-week gait training program combined with simultaneous blood flow restriction (BFR).
Keywords
Cerebral palsy, Blood Flow Restriction, Walking training, Pediatric rehabilitation
Medical subject headings
Cerebral Palsy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 10-week gait training program combined with simultaneous blood flow restriction (BFR).Other

    The children will receive a 10-week intervention (1 week of habituation without BFR + 9 weeks with BFR) comprising 3 30-minute treadmill sessions per week. At each session, the first 5 minutes will enable a gradual increase in speed, and then the maximum tolerated walking speed will be sought. Maximum speed corresponds to the walking speed maintained by the child for an effort of between 5 and 7 on Borg's 10-point VAS. The rehabilitator will encourage the child to maintain this speed and provide feedback on performance. The BFR setting will maintain an occlusion, at the root level of both lower limbs, of 60% of the total occlusal pressure.

Study groups in NCT06533956
Study groupRoleWhat they receive
gait training associated with BFRExperimentalThe children will receive a 10-week intervention (1 week of habituation without BFR + 9 weeks with BFR) comprising 3 30-minute treadmill sessions per week. At each session, the first 5 minutes will enable a gradual increase in speed, and then the maximum tolerated walking speed will be sought. Maximum speed corresponds to the walking speed maintained by the child for an effort of between 5 and 7 on Borg's 10-point VAS. The rehabilitator will encourage the child to maintain this speed and provide feedback on performance. The BFR setting will maintain an occlusion, at the root level of both lower limbs, of 60% of the total occlusal pressure.
Receives: Other: 10-week gait training program combined with simultaneous blood flow restriction (BFR).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparison of changes in walking speed with standard rehabilitation and with gait training associated with BFR.

    The evaluation criterion is the change in walking speed between D-70-J0 and D0-J+70.

    Measured: Patients' walking speed will be compared between Day -70 to Day 0 (standard rehabilitation) and Day 0 to Day +70 (gait training program + BFR)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Aug 2024
  2. Study start31 Oct 2024
  3. Primary completion12 Aug 2025
  4. Study completion1 Oct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
13 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06533956
Sponsor's protocol ID
49RC23_0258
Acronym
EMBRIN
Status last verified
Jun 2026
First submitted
23 Jul 2024
Last updated
16 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be shared upon reasonable request. Only de-identified data will be shared. Any data collected during the study may be shared. The protocol will be shared initially. Other documents may be shared at a later date upon request (e.g., the CRF to allow a collaborator to select the data they wish to access). The recipients of the data will be researchers. The data will be available for any purpose deemed relevant by the study investigator, based on a protocol provided by the requester, after verification of the obtaining of regulatory approvals, including the favorable opinion of an ethics committee.

Publications

  • Christiaens A, Dinomais M, Gilquin V, Coelho A, Carcreff L, Loiez A, Demas J. Blood flow restriction during walking training in bilateral cerebral palsy (EMBRIN): a pilot feasibility study protocol. BMJ Open. 2026 Feb 12;16(2):e110636. doi: 10.1136/bmjopen-2025-110636.

    PubMed 41689222

Questions about this trial

What is this clinical trial studying?

A study testing 10-week gait training program combined with simultaneous blood flow restriction (BFR). in people with Cerebral Palsy, run by University Hospital, Angers at 2 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 16 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Adélie Christiaens (2 41 35 18 04 ext. +33, adelie.christiaens@univ-angers.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparison of changes in walking speed with standard rehabilitation and with gait training associated with BFR. (time frame: Patients' walking speed will be compared between Day -70 to Day 0 (standard rehabilitation) and Day 0 to Day +70 (gait training program + BFR)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06533956, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jun 2026; AzTrials last refreshed its copy on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in